-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK INITIATES PHASE 3 KANDLELIT-007 TRIAL EVALUATING CALDERASIB (MK-1084), AN INVESTIGATIONAL ORAL KRAS G12C INHIBITOR, IN COMBINATION WITH KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) IN CERTAIN PATIENTS WITH ADVANCED NSCLC

路透·01/07/2026 11:50:04

登錄查看新聞詳情